RationaleTreatment of multi-drug resistant Tuberculosis (MDR-TB) is challenging because it mostly relies on drugs with lower efficacy and greater toxicity than those used for...

Diagnostic categories for non-death serious reports of adverse events after human diploid cell rabies vaccine (HDCV, Imovax) vaccine in VAERS among persons vaccinated January 1,...

Continuous renal replacement therapy indications, treatment parameters, adverse events, citrate accumulation.

SMQ codes related with hepatic disorder and renal disorder.

BackgroundLenalidomide could effectively induce red blood cell (RBC) transfusion independence (TI) in patients with lower-risk (Low/Intermediate-1) myelodysplastic syndrome...

Demographics by cohort and treatment arm.

Characteristics of 74 patients: 57 successful vs 17 unsuccessful outcome.

BackgroundCabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral...

Characteristics of included studies.

Structural equation modelling results.

Trial schedule.

BackgroundWe performed a systematic review to assess whether we can quantify the underreporting of adverse events (AEs) in the published medical literature documenting the...

Information and discussion among mothers (N = 1,660a) in Rachuonyo, western Kenya, by treatment group, Mtoto Msafi Mbili Study, September 2014 –July 2016.

Efficacy outcomes at week 24 (observed cases) and at endpoint (ITT-LOCF population).

Characteristics of the Trials Included in this Study.

Adverse events—safety population (N = 59).

GCTB sparse shrunk LD matrices from 2.8M common variants from the UK Biobank. Part AC of AA, AB, AC, AD and AE

BackgroundPediatric Phase I cancer trials are critical for establishing the safety and dosing of anti-cancer treatments in children. Their implementation, however, must contend...

Multivariable Conditional Logistic Regression for occurrence of a severe AE (Grade ≥3) (n = 1442) and for occurrence of a severe AE (Grade ≥3) after start of Cycle 2 (n = 1366).

Comparisons of responder rates at week 24 in patients with MMSE < 20.